Recombinant Human Growth Hormone Fragment 176-191, often abbreviated as HGH Fragment 176-191, is a modified form of amino acids 176-191 of the GH polypeptide. This peptide fragment is designed to mimic the fat-burning part of the human growth hormone (HGH), making it an area of interest for research in obesity and metabolic disorders. Unlike the full HGH molecule, this fragment does not promote growth or insulin resistance, focusing instead on its potential to accelerate lipolysis (the breakdown of fats) and inhibit lipogenesis, the conversion of non-fat food materials into body fat.
HGH Fragment 176-191 is synthesized recombinantly, which means it is produced in a laboratory using genetic engineering techniques. This process involves inserting the specific gene sequence that codes for this peptide into bacteria or other cells, which then produce the peptide as they grow. The fragment is then harvested, purified, and prepared for research purposes.
In studies, HGH Fragment 176-191 has been shown to increase the breakdown of fatty tissue without the side effects associated with full-length HGH, such as effects on insulin sensitivity or cell proliferation. Its action is believed to be mediated through the beta-3-adrenergic receptors, which play a role in the regulation of fat metabolism. This specificity makes it a subject of interest for potential therapeutic uses in treating conditions like obesity and metabolic syndrome, where increased fat metabolism can be beneficial.
It's important to note that while HGH Fragment 176-191 shows promise in preclinical models, its safety, efficacy, and regulatory approval status for use in humans must be thoroughly established through clinical trials. Currently, its use is primarily confined to research settings to understand its potential and mechanism of action in fat metabolism better.